** Disc Medicine's shares down 1.9% to $59.35 premarket as biopharma firm looks to raise equity

** Watertown, Massachusetts-based firm late Tues $200 mln offering consisting of stock and pre-funded warrants

** Co plans to use net offering proceeds to fund research and clinical development of its product candidates, to support potential commercialization of its treatment for erythropoietic protoporphyria $(EPP.UK)$, a

rare disease that causes painful sensitivity to light

** IRON shares on Tues rose nearly 4% to close at $60.52 after co received from US FDA for

** Jefferies, Leerink, Stifel and Cantor jt bookrunners for the equity offering

** Through Tues, IRON shares down 4.5% to begin 2025. Stock's 1-yr high is $77.60 (Mar 4) and 1-yr low is $25.60 (Apr 1)

(Lance Tupper is a Reuters market analyst. The views expressed are his own) ((lance.tupper@tr.com 1-646-279-6380))